At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 240 enrolled
Drug / intervention
Teneligliptin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Teneligliptin and Teneligliptin + Sulfonylurea for Type 2 Diabetes Mellitus. Completed, enrolled 240 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients with type 2 Diabetes for 52 weeks administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
Primary CompletionJul 2011
First PostedDec 2014
TodayJul 2026
First PostedDec 11, 2014
Enrollment StartAug 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.6 years ago
Interventions
Teneligliptindrug
Teneligliptin for 52 weeks
Teneligliptin + Sulfonylureadrug
Teneligliptin for 52 weeks in combination with sulfonylurea